PATIENTS TREATED WITH Research Articles

REDUCED RV FUNCTION IS ASSOCIATED WITH MORTALITY IN COVID-19 PATIENTS TREATED WITH ECMO

REDUCED RV FUNCTION IS ASSOCIATED WITH MORTALITY IN COVID-19 PATIENTS TREATED WITH ECMO

MP692ELEVATED FGF23-LEVELS IN DIALYSIS PATIENTS TREATED WITH ALUMINUM BASED PHOSPHATE BINDERS

MP692ELEVATED FGF23-LEVELS IN DIALYSIS PATIENTS TREATED WITH ALUMINUM BASED PHOSPHATE BINDERS

Colonic Stenting in the Management of Acute Left-sided Malignant Colonic Obstruction is Oncologically Safe?

The management of patients presenting with acute large bowel obstructioncaused by left sided colorectal cancer is still debated.Colonic stenting (CS) seems to be a good therapeutical option toemergency surgery: it is able to convert an urgent situation in anelective one. Lately conflicting results were published about thistechnique used as bridge to surgery in comparison with the emergencysurgery in terms of oncologic safety and recurrence rate.Actually self expandable metallic stents (SEMS) are not “allowed”to treat potentially curable patients. Data reported in literatureshow that colonic stenting improves primary anastomosis ratewith a low stoma creation in comparison with emergency surgery,enhancing patients’ quality of life, without differences in terms ofmortality and morbidity rate. According to available data, at oneyear follow up time, the recurrence rate is higher in patients treatedwith stent, with no statistical difference in terms of disease freesurvival and overall survival.Endoscopist’s experience, type of colic obstruction (partial or total),type of stent, insertion technique and timing of surgery arefundamental to reach CS technical and clinical success.Oncologic (un)-safety of colonic stenting has to be still investigatedand confirmed by medium and long term follow up of largeprospective studies and randomized controlled trials comparingSEMS and ES.

RAPID ONSET OF COGNITIVE IMPROVEMENTS IN A SUBSET OF MILD AND MODERATE ALZHEIMER’S PATIENTS TREATED WITH T3D-959: INTERIM RESULTS OF A PHASE 2A OPEN LABEL CLINICAL TRIAL

RAPID ONSET OF COGNITIVE IMPROVEMENTS IN A SUBSET OF MILD AND MODERATE ALZHEIMER’S PATIENTS TREATED WITH T3D-959: INTERIM RESULTS OF A PHASE 2A OPEN LABEL CLINICAL TRIAL

MP87-02 PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AND ESTABLISHMENT OF NOVEL RISK STRATIFICATION MODEL IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH DOCETAXEL CHEMOTHERAPY

You have accessJournal of UrologyProstate Cancer: Advanced III1 Apr 2015MP87-02 PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AND ESTABLISHMENT OF NOVEL RISK STRATIFICATION MODEL IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH DOCETAXEL CHEMOTHERAPY Yoshihiro Nakagami, Jun Nakashima, Yoshio Ohno, Ohori Makoto, and Masaaki Tachibana Yoshihiro NakagamiYoshihiro Nakagami More articles by this author , Jun NakashimaJun Nakashima More articles by this author , Yoshio OhnoYoshio Ohno More articles by this author , Ohori MakotoOhori Makoto More articles by this author , and Masaaki TachibanaMasaaki Tachibana More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1947AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Docetaxel (DTX) therapy is the standard treatment for castration-resistant prostate cancer (CRPC). The present study was undertaken to investigate independent prognostic factors and develop a stratification model of survival in CRPC patients treated with DTX therapy. METHODS The present study included 101 CRPC patients treated with DTX therapy from December 2003 to October 2013 in a single institution. We used the combination of docetaxel (DTX), estramustine phosphate (EMP) and hydrocortisone every 3 weeks. Associations of clinical factors with survival were analyzed using univariate and multivariate analyses. RESULTS The average number of treatment courses was 11. Median overall survival (OS) time was 21 months. In univariate analyses, patients with pain, impaired performance status, hemoglobin (Hb) ≤ 11 mg/dl, neutrophil-to-lymphocyte ratio (NLR) ≥ 2.6, lactate dehydrogenase ≥ 230 IU/L, PSA (at the initiation of DTX therapy) ≥ 110 ng/ml, alkaline phosphatase ≥ 650 IU/L and C-reactive protein (CRP) ≥ 2 mg/dl showed significantly lower survival rates than their respective counterparts. On the other hand, bone metastasis, age, PSA doubling time and lymph node metastasis were not significantly associated with OS. Multivariate analysis showed that presence of pain (hazard ratio [HR] 3.60, p < 0.001), CRP ≥ 2 mg/dl (HR 3.49, p = 0.002), impaired performance status (HR 2.75, p = 0.004), Hb ≤ 11 mg/dl (HR 1.93, p = 0.021), and NLR ≥ 2.6 (HR 1.98, p = 0.031) were independent predictors of OS. Using these 5 statistically significant variables, patients were stratified into 3 risk groups: low (HR = 1 – 3.60), intermediate (HR = 3.82 – 34.55), and high (HR = 34.68 – 132.03). The differences among the three groups were statistically significant CONCLUSIONS Elevation of NLR was an independent prognostic factor as were presence of pain, elevated CRP, impaired performance status and low Hb and the combination of these factors can stratify OS risks in CRPC patients treated with DXT therapy. Our risk stratification model may be useful to identify patients with poor prognosis, who might be good candidates for innovative treatment. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e1084 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Yoshihiro Nakagami More articles by this author Jun Nakashima More articles by this author Yoshio Ohno More articles by this author Ohori Makoto More articles by this author Masaaki Tachibana More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

MP4-14 LONG-TERM CANCER CONTROL OUTCOMES IN PROSTATE CANCER (PCA) PATIENTS TREATED WITH ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP): A MULTI-INSTITUTIONAL DATABASE ANALYSIS.

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I1 Apr 2015MP4-14 LONG-TERM CANCER CONTROL OUTCOMES IN PROSTATE CANCER (PCA) PATIENTS TREATED WITH ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP): A MULTI-INSTITUTIONAL DATABASE ANALYSIS. Firas Abdollah, Dane Klett, Akshay Sood, Jesse Sammon, Daniel Pucheril, Burkhard Beyer, Nicola Fossati, Giorgio Gandaglia, Craig Rogers, Hans Stricker, Wooju Jeong, James Peabody, Alexander Haese, Francesco Montorsi, Markus Graefen, Alberto Briganti, and Mani Menon Firas AbdollahFiras Abdollah More articles by this author , Dane KlettDane Klett More articles by this author , Akshay SoodAkshay Sood More articles by this author , Jesse SammonJesse Sammon More articles by this author , Daniel PucherilDaniel Pucheril More articles by this author , Burkhard BeyerBurkhard Beyer More articles by this author , Nicola FossatiNicola Fossati More articles by this author , Giorgio GandagliaGiorgio Gandaglia More articles by this author , Craig RogersCraig Rogers More articles by this author , Hans StrickerHans Stricker More articles by this author , Wooju JeongWooju Jeong More articles by this author , James PeabodyJames Peabody More articles by this author , Alexander HaeseAlexander Haese More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , Markus GraefenMarkus Graefen More articles by this author , Alberto BrigantiAlberto Briganti More articles by this author , and Mani MenonMani Menon More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.157AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The last decade saw widespread dissemination of RALP as the preferred surgical method to treat clinically localized PCa. Most available data regarding cancer control outcomes are based on merely the surgical margin status and pathological stage at surgery. Indeed, long-term oncological follow-up data for RALP are still lacking. To address this void, we set to evaluate the biochemical recurrence (BCR)-free survival rate and clinical recurrence (CR)-free survival rate in a large multi-institutional database of PCa patients treated with RALP. METHODS 7105 patients who underwent RALP ± adjuvant treatment and pelvic node dissection between 2002–2013 at 3 tertiary care centers were included. All had complete baseline and follow-up data. BCR defined as PSA value ≥0.2 ng/ml on two consecutive occasions. Kaplan-Meier curves estimated 10-year BCR-free and CR-free survival rates. Cox logistic regression tested the relationship between baseline clinical and pathological characteristics (in 2 separate models) and 2 endpoints, namely post-op BCR rate, and post-op CR rate. RESULTS Mean (median) age and PSA at surgery were 60.6 (61) yrs and 6.6 (5.3) ng/ml, respectively. Most had a biopsy GS 2–6 (52.6%), clinical T1 stage (75.0%), D'Amico intermediate-risk disease (45.1%), pathological GS 7 (60.2%), and pathological T2 stage (55.8%). Overall, 23.5% and 3.1% respectively had positive surgical margins and lymph node invasion (LNI) at surgery. Only 2.2% received any adjuvant treatment. Mean (median) follow-up time was 49.4 (40.2) months. At 10-years, BCR-free survival rate was 72.7%, and it was 88.3, 66.5, and 50.4% in patients with respectively clinical low-, intermediate-, and high-risk disease according to D'Amico. Likewise, 10-year CR-free survival rate was 96.5%, and it was 99.9, 97.0, and 87.5% respectively in the aforementioned risk groups. At multivariable analysis (MVA), PSA, clinical stage and biopsy GS were independent predictors of both BCR and CR rates (all p<.01). Likewise, in a separate MVA model, PSA, pathological stage, pathological GS, margin status and LNI status were independent predictors of both BCR and CR rates (all p<0.02). CONCLUSIONS Our findings address the lack of literature regarding cancer control outcomes in pts treated with RALP. Given the very low use of adjuvant treatment in our cohort, our results represent the natural history of the disease from surgery to BCR. RALP appears to confer favorable cancer control long-term, comparable to open surgery. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e32 Peer Review Report Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Firas Abdollah More articles by this author Dane Klett More articles by this author Akshay Sood More articles by this author Jesse Sammon More articles by this author Daniel Pucheril More articles by this author Burkhard Beyer More articles by this author Nicola Fossati More articles by this author Giorgio Gandaglia More articles by this author Craig Rogers More articles by this author Hans Stricker More articles by this author Wooju Jeong More articles by this author James Peabody More articles by this author Alexander Haese More articles by this author Francesco Montorsi More articles by this author Markus Graefen More articles by this author Alberto Briganti More articles by this author Mani Menon More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy.

Objectives: The objective of this study was to determine the incidence of retinopathy in chronic hepatitis C patients treated with Pegylated interferon alpha 2a and Ribavirin.Methods: This descriptive case series study was conducted in Medical Unit II of the Jinnah Hospital Lahore from September 2012 to February 2013. One hundred chronic hepatitis C patients visiting Medical Unit II outpatient department fulfilling inclusion criteria were selected for this study via non probability purposive sampling. Patients were started on pegylated interferon and ribavirin combination therapy. Subjects were subjected to dilated eye fundoscopic examination at the start of therapy and then after three months of the therapy.Results:One hundred patients were included in this study. Out of these 100 patients 5% developed retinopathy whereas fundus examination was normal in rest of the patients.Conclusion:Interferon therapy can lead to retinopathy. Periodic fundoscopic examinations help in early detection and prevent progression to permanent visual loss.

MP56-16 THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.

MP56-16 THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.

Periodontitis disease as a model of inflammation and bone remodelling to study osteoarthritis drug effects. Results from a pilot study in OA patients treated with chondroitin sulfate

Periodontitis disease as a model of inflammation and bone remodelling to study osteoarthritis drug effects. Results from a pilot study in OA patients treated with chondroitin sulfate

More Questions Than Answers in 6 Cases

Bechara and colleagues1 report a series of 12 patients treated over 11 years who sustained intraoperative carotid artery introducer sheathplacementduringattempted jugular vein cannulation. Six earlier patients were treated with open carotid artery exploration and primary repair, whereas the more recent 6 patients were treated with percutaneous closure using a suture-mediated closure device. No patients in either group had neurological events or other complications. However, the mean duration of treatment was shorter in the endovascular group than the operative group, 6 vs 32 minutes, respectively. The authors conclude that endovascular closure is as safe and effective as operative repair but more expeditious. Is it possible to extend the authors’ findings to the general group of patients having catheters placed into the carotidartery?Arterialpunctureduring internal jugularveincatheterization occurs in approximately 6% to 9% of cases.2 The low frequency of the authors’ cases, their carotid artery catheterplacement in theoperating roombyanesthesiologists, and their repairbyexperiencedvascularsurgeonssuggest that these cases are a highly selected group at low risk for complications after any repair.However, ifmost carotidartery catheterplacements occur outside the operating roomandoften involve inexperienced trainees who do not use ultrasonographic guidance, is endovascular repair appropriate for these patients? Interestingly, thecathetersplaced inthisstudywereall8.5F introducer sheaths, facilitating endovascular closure; smaller central venous catheters may be more amenable to manual compression or repair with a single Prolene stitch. The authors’ conclusion that “repair of the carotid artery puncture site” is mandatory seems unfounded given the lack of patients treatedwith compression, the lack of smaller catheters in the group, and the lack of a prospective trial. This case series is certainly intriguing and suggests that some patientsmay be treatedwith endovascular techniques. However, that group of patients is not yet clearly defined and the algorithm is not well understood. For example, angiographywas performed selectively in this series, in addition to ultrasonography, but this additional risk of stroke requires justification; who should undergo angiography in this scenario? Is it mandatory to inspect the runoff bed for emboli? The role of endovascular treatment continues to evolve, especially when performed by endovascular leaders. However, success in 6 attempts does not replace the standard of care; a single complicationmay have led to devastating complications. The gold standard for carotid artery repair remains open surgical exploration; the time savings (mean, 26 minutes) must be weighed against the cost of the closure device aswell.Despite theauthors’ success in6patients,wecaution readers against the quick and broad adoption of this method and suggest its use only in selected cases, such as in sites that have difficult surgical exposure.3

F4.1 Intramedullary nailing of Grade II and Grade III open diaphyseal femoral and tibial fractures

between 3 and 11 cm proximal to the plafond. Eighteen patients were treated with closed IMN (Group I) and 28 patients were treated with PLP fixation (Group II). Patients with at least 1-year follow-up were included. The mean age was 40.5 (range:16–70) years; 78% of the patients were men. The rates of union, malunion, malalignment (defined as >5 degrees of angulation in any plane), infection, and removal of implants were compared according to final outcomes. The average followup period was twenty eight months. Twenty-one fractures (27%) were open. Results: The age and gender were similar in both groups. None of the patients had deep infection. Two patients (7%) had nonunion in Group II. Two patients treated with IMN, compared with three patients treatedwith PLP, had amalalignment. Significant differences were found with regard to union time between the two groups (p <0.05). The average union times were 16 weeks in Group I and 19 weeks in Group II. Conclusion: For earlier union time compared to PLP, we advise considering the use of IMN for extra-articular fractures in the distal third of the tibia.

PDB36 Reduced Rates of Hypoglycemia Lead to Cost Savings for Type 2 Diabetic Patients Treated with Saxagliptin Versus Sulphonlyurea in Actual Clinical Practice

REDUCED RATES OF HYPOGLYCEMIA LEAD TO COST SAVINGS FOR TYPE 2 DIABETIC PATIENTS TREATED WITH SAXAGLIPTIN VERSUS SULPHONLYUREA IN ACTUAL CLINICAL PRACTICE Becker DL1, Thayer SW2, Zhang B3, Skornicki M4, Graham JP3, Bell KF3 1OptumInsight, Burlington, ON, Canada, 2OptumInsight, San Francisco, CA, USA, 3Bristol-Myers Squibb Company, Plainsboro, NJ, USA, 4OptumInsight, Medford, MA, USA OBJECTIVES: To estimate the clinical and economic impact of saxagliptin (SAXA) versus sulfonylurea (SU), both with metformin (MET), on the reduction of hypoglycemia among individuals with type 2 diabetes (T2D) in clinical practice. METHODS: Our analysis combined data from several sources to estimate outcomes on a perpatient and health plan-population level. Patient survey data (n 91) were used to estimate real-world rates of hypoglycemia for patients treated with SU MET, while the relative risk reduction observed in the pivotal SAXA clinical trial was applied to estimate the proportion of patients receiving SAXA MET who experience 1 hypoglycemia event. Costs associated with hypoglycemia treatment were obtained from an administrative claims analysis (n 813) and epidemiologic data were obtained from the literature. Costs are reported in 2011 USD. RESULTS: Treatment with SAXA MET was estimated to reduce the probability of experiencing 1 event from 68.1% to. 5.6% (net -62.5%). At these rates, resultant annual costs when all diabetes-related medical claims were considered were $435/patient treated with SU MET and $36/patient treated with SAXA MET, an annual cost savings of $399/patient receiving SAXA MET. If 50% of eligible patients in a 100,000-member health plan were switched from SU MET to SAXA MET, the net diabetes-related cost savings due to reduced hypoglycemia was estimated at $216,000 in 2011, increasing to $230,000 by 2013 (net savings of $0.19 per-member-per-month). When only confirmed events [i.e., symptom(s) blood glucose 70mg/dL] were considered, the net reduction in event rate was -24.2%, with annual cost savings predicted at $209/patient or $113,000-121,000 on a health plan level (savings of $0.10 per-member-per-month). CONCLUSIONS: When clinical trial results for SAXA MET are translated to actual clinical practice, the model predicts the lower rate of hypoglycemia (considering all events as well as confirmed events only) relative to treatment with SU MET will result in considerable cost savings on both a per-patient and health-plan level.

Comparison of haemostatic efficacy for endoscopic injection therapy of epinephrine and combination therapy of epinephrine and hemoclips for bleeding peptic ulcers

Endoscopic injection therapy of epinephrine is safe and effective in the treatment of bleeding peptic ulcer, but with high risk of rebleeding. The combination therapy of epinephrine and hemoclips could lead to a reduction of rebleeding and a potential reduction in mortality. To investigate the efficacy and safety of epinephrine injection therapy and combination therapy with epinephrine and hemoclips in treating bleeding peptic ulcers. A prospective randomized study included 58 patients with bleeding gastric or duodenal ulcer. In 30 patients endoscopic injection therapy with diluted epinephrine was applied (group I), while in 28 patients combination therapy of epinephrine and hemoclips was applied (group II). RESULTS; Initial haemostasis was achieved in most patients treated with epinephrine injection therapy (93.3%) and patients treated with combination therapy of epinephrine and hemoclips (96.4%). After initial haemostasis was achieved rebleeding was significantly more frequent in the patients treated with epinephrine (28.5%) than in the patients treated with combination therapy (3.7%, p < 0.05). Two patients treated with epinephrine injection therapy were subjected to surgical intervention, whereas no patient treated with combination therapy needed surgery. Lethal ending occurred in one patient treated with epinephrine and in one patient treated with combination therapy. The difference between the two groups of patients in need for surgical intervention and mortality was not statistically significant. Combination therapy with epinephrine and hemoclips is more efficient than epinephrine alone in the treatment of bleeding peptic ulcers.

URINARY PHENOLS IN PATIENTS TREATED WITH ALPHA-METHYLDOPA.

Journal Article Urinary Phenols in Patients Treated with α-Methyldopa Get access A W Stott, A W Stott Group Pathological Laboratory, Warwick Search for other works by this author on: Oxford Academic Google Scholar R Robinson R Robinson Group Pathological Laboratory, Warwick Search for other works by this author on: Oxford Academic Google Scholar Journal of Pharmacy and Pharmacology, Volume 15, Issue 1, September 1963, Pages 773–774, https://doi.org/10.1111/j.2042-7158.1963.tb12876.x Published: 12 April 2011 Article history Received: 12 September 1963 Published: 12 April 2011

1741 COULD PATIENT AGE INFLUENCE TUMOR RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH BCG IMMUNOTHERAPY?

You have accessJournal of UrologyBladder Cancer: Superficial1 Apr 20111741 COULD PATIENT AGE INFLUENCE TUMOR RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH BCG IMMUNOTHERAPY? Kazuyuki Yuge, Eiji Kikuchi, Kazuhiro Matsumoto, Nobuyuki Tanaka, Toshikazu Takeda, Akira Miyajima, Ken Nakagawa, and Mototsugu Oya Kazuyuki YugeKazuyuki Yuge Tokyo, Japan More articles by this author , Eiji KikuchiEiji Kikuchi Tokyo, Japan More articles by this author , Kazuhiro MatsumotoKazuhiro Matsumoto Tokyo, Japan More articles by this author , Nobuyuki TanakaNobuyuki Tanaka Tokyo, Japan More articles by this author , Toshikazu TakedaToshikazu Takeda Tokyo, Japan More articles by this author , Akira MiyajimaAkira Miyajima Tokyo, Japan More articles by this author , Ken NakagawaKen Nakagawa Tokyo, Japan More articles by this author , and Mototsugu OyaMototsugu Oya Tokyo, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2068AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The effect of BCG therapy in elderly patients with non-muscle invasive bladder cancer (NMIBC) has not yet been fully evaluated. The aim of the present study was to evaluate whether patient age could influence the response to BCG therapy concerning the prevention of tumor recurrence and/or the side effects of BCG therapy. METHODS A total of 1252 cases treated with TUR-BT for NMIBC between 1981 and 2005 at our institution were reviewed, and 447 cases underwent BCG therapy after TUR-BT were identified in the present study. The patients were divided into 4 age categories; under 55 (N=86), 55 to 64 (N=143), 65 to 74 (N=132), and equal or older than 75 (N=86). Patient age was analyzed to determine if it affected subsequent tumor recurrence. Side effects (fever and BCG cystitis) were classified as minor or major and were analyzed. RESULTS The median follow-up period was 4.2 years. The 5 and 10-year recurrence-free survival rates for each age group were 57.6% and 53.2%, 63.3% and 47.6%, 58.5% and 47.9%, and 50.6% and 35.8%, respectively. Kaplan-Meier curves of recurrence-free survival rates showed that patients aged 55 to 64 had significantly better tumor-free survival period compared to equal or older than 75 group (p=0.029). However, in multivariate analysis, the presence of prior bladder cancer (p=0.005, HR:1.572) and tumor grade 3 (p=0.030, HR:1.377) were independent risk factors for subsequent tumor recurrence. In addition, the analyses showed that the incidence of fever was significantly higher in the younger group; 9.3% in equal or older than 75 group, compared to 24.4% in the under 55 group, 18.9% in the 55–64 group, and 18.2% in the 65–74 group (p=0.0081, p=0.0511, and p=0.0702, respectively). On the contrary, the incidence of minor or major symptoms of cystitis in the under 55 group was 30.2%, which was significantly lower than that of the 55–64 group (48.3%), 65–74 group (56.1%), and equal or older than 75 group (46.5%) (p=0.0074, p=0.0002, and p=0.0282, respectively). Kaplan-Meier analysis was demonstrated to evaluate whether the presence of side effect could predict the effect of BCG therapy. However, there was no significant correlation between subsequent tumor recurrence and the presence of each side effect (fever or BCG cystitis) in any age group. CONCLUSIONS Patient age could not influence tumor recurrence in patients with bladder cancer treated with BCG therapy. Although there were no significant correlation between subsequent tumor recurrence and presence of side effects, incidence of fever and BCG cystitis were related to the patient age groups. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e699 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kazuyuki Yuge Tokyo, Japan More articles by this author Eiji Kikuchi Tokyo, Japan More articles by this author Kazuhiro Matsumoto Tokyo, Japan More articles by this author Nobuyuki Tanaka Tokyo, Japan More articles by this author Toshikazu Takeda Tokyo, Japan More articles by this author Akira Miyajima Tokyo, Japan More articles by this author Ken Nakagawa Tokyo, Japan More articles by this author Mototsugu Oya Tokyo, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

1181 PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL IL-28B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN

1181 PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL IL-28B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN J.G. McHutchison, A.J. Thompson, I.M. Jacobson, T.D. Boyer, E.R. Schiff, G.T. Everson, J.M. Vierling, M.L. Shiffman, R.S. Brown, A.M. Di Bisceglie, S.C. Gordon, W.M. Lee, Z. Guo, T.H. King, B. Armstrong, T.C. Rodell, D. Apelian. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, Center for Liver Diseases, University of Miami School of Medicine, Miami, FL, Department of Medicine, University of Colorado Denver, Aurora, CO, Department of Medicine and Surgery, Baylor College of Medicine, St. Luke’s Episcopal Hospital, Houston, TX, Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, Columbia University College of Physicians & Surgeons, New York, NY, Saint Louis University, St. Louis, MO, Henry Ford Hospital, Detroit, MI, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, GlobeImmune, Inc., Louisville, CO, QST Consultations, LTD, Allendale, MI, USA E-mail: mchut001@mc.duke.edu

Muito baixo peso ponderal em pacientes tratados com angioplastia coronária: impacto na mortalidade precoce e tardia

SUMMARY Very Low Ponderal Weight in Patients Treatedwith Coronary Angioplasty: Impact on Early andLate Mortality Background: Patients with very low weight treated withpercutaneous coronary intervention have a greater risk ofcomplications during hospitalization. So far, there havebeen no studies to evaluate the long-term effect of lowweight after coronary angioplasty in the Brazilian population. Methods: A total of 3,687 patients were divided into twogroups according to their body mass index (BMI), calculatedby dividing the weight in kilograms by the height inmetres squared: low-weight group (BMI 20 kg/m²;3,562 patients). The in-hospital mortality was evaluatedprospectively during first admission. After discharge, deathoccurrence was assessed by reviewing hospital recordsand through telephone contact. Results: Patients with BMI≤ 20 kg/m² presented weight, height, and BMI averagesof 49.4 ± 7.1 kg, 1.62 ± 0.10 m, and 18.7 ± 1.1 kg/m²,respectively. The weight, height and BMI of patients withBMI > 20 kg/m² was 74.4 ± 13.8 kg, 1.64 ± 0.09 m, and27.3 ± 4.3 kg/m², respectively (p 20 kg/m²2.5 years after angioplasty (19.4% vs. 6.9%, respectively;hazard ratio [HR]: 2.51; 95% confidence interval [95%CI]: 1.61-3.91; p < 0.01). After multivariate adjustment forother risk factors, the presence of BMI ≤ 20 kg/m² persistedas an independent factor associated to increased mortality(HR: 2.04; 95% CI: 1.28-3.25; p < 0.01).

NOVEL GENE POLYMORPHISMS IN THE IMPDH2 GENE MAY ACCOUNT FOR NEUTROPENIA AND OTHER SIDE EFFECTS IN PATIENTS TREATED WITH MYCOPHENOLIC ACID (MPA).

NOVEL GENE POLYMORPHISMS IN THE IMPDH2 GENE MAY ACCOUNT FOR NEUTROPENIA AND OTHER SIDE EFFECTS IN PATIENTS TREATED WITH MYCOPHENOLIC ACID (MPA).

PAR10 IMPROVING THE SENSITIVITY OF PHYSICAL FUNCTION MEASURES IN RHEUMATOID ARTHRITIS: USE OF ITEM RESPONSE THEORY IN PATIENTS TREATED WITH ABATACEPT (CTLA4IG)

PAR10 IMPROVING THE SENSITIVITY OF PHYSICAL FUNCTION MEASURES IN RHEUMATOID ARTHRITIS: USE OF ITEM RESPONSE THEORY IN PATIENTS TREATED WITH ABATACEPT (CTLA4IG) Martin M, Emery P, Kosinski M,Ware J, Li T,Williams R, Maclean R, Bjorner J Quality Metric, Inc, Lincoln, RI, USA; University of Leeds, Leeds, United Kingdom; Bristol-Myers Squibb, Princeton, NJ, USA; Bristol-Myers Squibb, Brussels, Belgium OBJECTIVES: The Health Assessment Questionnaire (HAQ) and the Modified HAQ (MHAQ) are examples of common short-forms of physical function used to measure improvement in the treatment of rheumatoid arthritis (RA) which have been associated with ceiling problems. These problems, inherent to short-form surveys, pose risks of failing to detect a treatment response in clinical trials. Item Response Theory (IRT) methods were used to examine the properties of two physical function measures and construct a combined measure to better detect changes in disease activity and treatment response. METHODS: Data were from a 12-month, double-blind, multi-center study of 339 RA patients on a background of methotrexate randomized to Abatacept at 2mg/kg, at 10mg/kg, or placebo. MHAQ and SF-36 (with its Physical Functioning scale, PF10) were administered at pretreatment and 3, 6, and 12 months post-treatment. IRT methods were used to examine the surveys’ measurement properties and compute new IRT-based physical function scores. Analyses of variance were used to assess sensitivity to changes in disease severity and treatment response. Relative validity coefficients were used to compare the measures. RESULTS: A Rasch IRT model fit the data. IRT-based scores successfully lowered the floor and raised the ceiling of the physical function measured. IRT-based scores were 30% more efficient than MHAQ and 50% more efficient than PF10 in discriminating among ACR groups. In discriminating among treatment groups, IRT-based scores were 25% more efficient than MHAQ and 12% more efficient than PF10 at 6-months; and 16% and 17% more efficient at 12-months based on observed effect sizes. CONCLUSIONS: Using IRT methodology to estimate a combined score for physical functioning lead to greater range of the construct measured. The improved measure, with greater measurement precision and sensitivity to treatment response, further confirmed the beneficial effect of Abatacept on physical function in the treatment of RA.

LOGISTIC REGRESSION AND SURVIVAL ANALYSIS OF 450 IMPOTENT PATIENTS TREATED WITH INJECTION THERAPY: LONG-TERM DROPOUT PARAMETERS

We report the dropout rate associated with intracavernosal self-injection for erectile dysfunction at long-term followup, and determine parameters related to dropout. Of 2,252 impotent patients evaluated during 9 years 450 (20%) enrolled in our self-injection program. Papaverine and phentolamine were given in 53% (initial treatment), prostaglandin E1 in 21%, and papaverine, phentolamine and prostaglandin E1 (triple mixture) in 26% of cases. Average injection volume for the 3 injection types was 0.52 cc. Data were retrospectively reviewed for patient dropout versus nondropout, specifically for type of drug, volume injected, changing treatment (from 1 drug and/or dosage to another), patient age, marital status, ethnic group, impotence duration and diabetes. Patient age ranged from 23 to 79 years (mean age 55). Of the patients treated at least 4 months 155 (35%) dropped out of the study. Mean treatment duration was 3.5 years. Logistic regression suggested that type of drug, changing treatment during the course of therapy and dosage (volume injected) were the only significant (p <0.05) parameters influencing dropout. Papaverine and phentolamine were twice as likely to lead to dropout as triple mixture or prostaglandin E1, and injection greater than 0.5 cc was more than twice as likely to lead to dropout. Demographic, ethnic, age and etiological factors had no significant effect on the overall dropout rate. The effectiveness of injection therapy was an underlying factor determining the long-term dropout rate for patients with erectile dysfunction. Other parameters or combinations of parameters that may influence patient dropout remain to be explored.